DUBLIN--(BUSINESS WIRE)--The "Sepsis - Treatment Report" report has been added to Research and Markets' offering.
This report is part two of a two-part series on hospital-treated sepsis. This report provides quantitative, objective data focused on the treatment of sepsis requiring hospitalization captured by hospitals contributing to Cerner Health Facts. This data provides real-world patient encounters and reflects real physician decisions and encounter characteristics (e.g. patient response to therapy and outcomes) in key areas, such as antimicrobial stewardship.
Sepsis is responsible for an estimated 12% of all hospital stays. At an average cost of $15,500 per occurrence, we estimate that hospitalizations for severe infections account for $212 billion in annual spending or 7% of total healthcare expenditure. In this report, we conduct an in-depth analysis of sepsis patient characteristics, medication management, costs, and laboratory testing.
Gram-positive bacteria are the likely causative agents of most sepsis infections. Physicians treat the vast majority of these infections with vancomycin, piperacillin-tazobactam, levofloxacin, and ceftriaxone. After confirmatory diagnosis, over half of sepsis patients undergo a change in antibiotic therapy.
Key Topics Covered:
1. Patient Flow
2. Executive Summary
3. Incidence and Impact of Disease
- Incidence
- Length of Stay
- Total Cost
4. Patient Demographics
- Age
- Insurance type
- Gender
- Region
- Mortality
- Comorbid Conditions
5. Patient Flow through the Hospital
- Admission Site
- Lab Testing
- Lab TAT
- Results
- Etiology
- Empiric Therapy
- Change in treatment
6. Drug Share for Key Therapeutics
- Most Common
- LOS
- APACHE Score
- Treatment Duration
- Product Dashboards
7. Outcomes of Treatment
- Antibiotic Usage
- Mortality
- Cost per Patient
8. Database Overview
9. Methodology
For more information about this report visit https://www.researchandmarkets.com/research/lps4gx/sepsis
